Dalan Animal Health, a pioneering bioscience company, has successfully closed a $3 million SAFE funding round with contributions from Good Growth Capital, Meach Cove Capital, and other global investors. This funding will propel the commercialization of Dalan’s innovative shrimp vaccine, a critical development in addressing disease challenges in global aquaculture. Following their successful honeybee vaccine launch, Dalan aims to expand its Innate Immunity Platform to new species, including poultry and other aquaculture species, to reduce antibiotic reliance and enhance disease prevention. Harris Komishane from Meach Cove Capital will join Dalan’s Board as an observer, offering strategic insights for growth. The shrimp vaccine, proven effective in clinical trials, targets diseases like the White Spot Syndrome Virus, which costs the shrimp industry billions annually. The funding will support manufacturing, regulatory processes, and market development for the vaccine’s commercial launch. Additionally, Dalan’s European subsidiary has received a €250,000 grant for honeybee disease surveillance, underscoring global interest in their technology.
Has Dalan Animal Health secured $3M to commercialize their shrimp vaccine?
